Table 3.
Subgroup analysis of prevalence of erectile dysfunction among testicular cancer survivors, 2020.
| Variables | Characteristics | Estimates (95% CI) | I2 tests with p-value |
|---|---|---|---|
| Study designs | Case-control | 50.02% (22.78%, 77.26%) | 96.1%, P = 0.000 |
| Cohort | 27.36% (19.23%, 35.48%) | 91.6%, P = 0.000 | |
| Cross-sectional | 38.66% (19.82%, 57.51%) | 97.4%, P = 0.000 | |
| Treatment modalities | Three treatments | 45.46% (27.23%, 63.70%) | 97.5%, P = 0.000 |
| Less three treatments | 26.5% (20.29%, 32. 71%) | 87.3%, P = 0.000 | |
| Measuring tools | IIEF | 40.50% (25.42, 55.58) | 97.5%, P = 0.000 |
| BMSFI | 31.49% (22.48,40.50) | 71.9%, P = 0.06 | |
| Others | 24.48% (18.30, 30.66) | 74.7%, P = 0.008 |
Others = International Index of Erectile Function and Brief Sexual Function Inventory, European Organization for Research and Treatment of Cancer (EORTC QLQ-PR25), nine-item generic questionnaire, and adverse health outcomes.